Contribution By Saipriya Iyer
The Filipino fast-food chain is expected to offer a good number of line ups
The store could be widely accepted by a large Filipino community in the province
Jollibee, a multinational fast food in chain of restaurants from Philippines, has r
IAC, a renowned technology holding company operating mostly in media and internet, and Match Group, an American internet company that operates several dating apps, have reportedly entered into a definitive agreement to separate their businesses. As p
It aims at providing medication to patients diagnosed with severe immune-mediated diseases
FDA approved fast track designation to ADX-2191 to treat PVR in September 2019
U.S headquartered biotechnology company – Aldeyra Therapeutics repor
22nd Century Group, a renowned plant biotechnology firm working at the forefront in tobacco harm reduction, reportedly announced the approval of marketing and sales of Moonlight® and Moonlight® Menthol brand cigarettes by the U.S. FDA.
The FDA h
Ashton Potter, a renowned New York based Information Technology and Services company, has reportedly announced new release of its ProLinc® solution to capture factory floor insights for automated manufacturers. New ProLinc® sensing module combines
Lately, Patient Assistance Programs (PAPs), cancer awareness initiatives from governments, growing prevalence of cancer globally are driving strong R&D initiatives and clinical trials are being conducted to find a treatment for several cancer typ
The partnership would help service providers to offer customers with next-generation endpoint protection.
In recent years, data security has become a major concern for both users and companies. Tech companies are increasingly seeking new avenues t
With rising levels of health-consciousness and awareness among consumers and the growing need for health tracking devices, numerous scientific innovations are coming into existence. One such innovation has recently been developed by digital health co
With an eye to cure ER+, HER2- breast cancer, G1 Therapeutics, Inc., a clinical-stage oncology company, has recently revealed updated data from the Phase 1b/2a clinical trial examining the its oral CDK4/6 inhibitor lerociclib along with fulvestrant.